Surgical Morbidity Associated With Administration of Targeted Molecular Therapies Before Cytoreductive Nephrectomy or Resection of Locally Recurrent Renal Cell Carcinoma
- 1 July 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 180 (1), 94-98
- https://doi.org/10.1016/j.juro.2008.03.047
Abstract
Purpose: Targeted molecular therapies such as bevacizumab, sunitinib and sorafenib before surgical resection hold promise as rational treatment paradigms for patients with metastatic or locally rec...Keywords
This publication has 17 references indexed in Scilit:
- Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient OutcomeClinical Cancer Research, 2007
- Sorafenib in Advanced Clear-Cell Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Presurgical therapy in metastatic renal cell carcinomaExpert Review of Anticancer Therapy, 2007
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- Biology and Clinical Development of Vascular Endothelial Growth Factor–Targeted Therapy in Renal Cell CarcinomaJournal of Clinical Oncology, 2005
- A Randomized Trial of Bevacizumab, an Anti–Vascular Endothelial Growth Factor Antibody, for Metastatic Renal CancerNew England Journal of Medicine, 2003
- Vascular Endothelial Growth Factor-Mediated Angiogenesis Inhibition and Postoperative Wound Healing in RatsJournal of Surgical Research, 2002
- Nephrectomy Followed by Interferon Alfa-2b Compared with Interferon Alfa-2b Alone for Metastatic Renal-Cell CancerNew England Journal of Medicine, 2001
- Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialThe Lancet, 2001
- Antibody Neutralization of Vascular Endothelial Growth Factor Inhibits Wound Granulation Tissue FormationJournal of Surgical Research, 2001